Kirk Lund is an expert in the field of Hematology. He went to University of Utah School of Medicine. He has 1 awards "Meaningful Use Stage 1 Certification". Kirk Lund is also published. He has 1 publication published. The lastest publication: "Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.' He accepts all Medicare patients.
NPI NUMBER | 1881686228 | |
NPPES Provider LastName | LUND | |
NPPES Provider FirstName | KIRK | |
NPPES Provider ZIPCode | 992042966 | |
NPPES Provider State | WA | |
Specialty Description | Medical Oncology | |
Total Claim Count | 908.0 | |
Distinct Opioid Count | 4.0 | |
Opioid Claim Count | 106.0 | |
Percent Opioid Claims | 11.67 |
National Provider Identifier [NPI] | 1881686228 |
Last Name Of The Provider | LUND |
First Name Of The Provider | KIRK |
View All |
![]() |
Dr. Stephen P. Anthony, DO |
![]() |
Dr. Joe U. Choi, MD
![]() |
![]() |
Dr. Arvind Chaudhry, MD
![]() |
![]() |
Dr. Kawal D. Chester, MD
![]() |
![]() |
Dr. Corliss L. Newman, MD
![]() |
![]() |
Dr. Robert H. Gersh, MD |
![]() |
Dr. Mei Dong, MD
![]() |
![]() |
Dr. Jeffrey T. Bunning, MD |
![]() |
Dr. Howard D. Stang, MD
![]() |